Objective: Currently, diagnosis of IgA nephropathy (IgAN) relies on renal biopsy. Most IgAN is progressive, however, renal biopsy cannot be done frequently for its invasive property. This study is to investigate non-invasive protein biomarkers of IgAN from urine supernatant. Methods: Urine supernatant was collected from 15 IgAN patients (Lee's grade I-II, III and IV-V, 5 in each group), 12 none-IgAN glomerular disease control (DC) patients (MCD, MN and FSGS, 4 in each group) and 5 normal control (NC). Urine sample were analyzed by Raybiotech protein array for searching differential expression of protein biomarkers. Candidate protein biomarkers were further validated in urine samples from other subjects, including 49 IgAN patients (Lee's grade I-II 8, grade III 31 and grade IV-V 10), 28 DC patients (MCD 8, MN 8 and FSGS 12) Objective: Most of IgA nephropathy (IgAN) is chronic progressive glomerulonephritis, with different clinical and pathological features. Evaluation of the disease by repeated renal biopsy is not practical due to its invasive procedure. Urinary sediment miRNAs are hopeful to serve as non-invasive biomarkers to assess kidney injury of IgAN. Methods: 52 biopsy-proven IgAN patients and 25 healthy controls were enrolled in this study. Urinary sediment miRNAs were extracted. Expressions of miR-34a, miR-205, miR-21, miR-146a and miR-155 were quantified by qPCR. ROC (receiver operating characteristic curve) was used to investigate the value of the miRNAs for predicting dignosis of IgAN and evaluating histopathological injury. The patients were treated according to the KDIGO guideline and followed up. The roles of miRNAs in reflecting theraputic efficacy and disease progression were analyzed. Results: (1) The IgAN group had significantly lower urinary miR-34a, miR-205, miR-155 but higher miR-21 levels than controls. Logistic regression analysis showed that urinary miR-34a 0.047, miR-205 0.209 and miR-21!0.461 were independent factors for diagnosis of IgAN. The ROC revealed that miR-205 0.125 and miR-21!0.891 can distinguish IgAN patients with moderate and severe tubular atrophy and interstitial fibrosis from those with mild tubular atrophy and interstitial fibrosis. (2) After 21.17 months follow-up, the level of proteinuria reduction (g/24h/month) was positively correlated with baseline urinary miR-21 and inversely correlated with miR-205. The subjects who achieved a complete remission (CR) had higher baseline urinary miR-205, and lower miR-21 than those without achieveing a CR. Conclusion: The levels of some urinary sediment miRNAs, especially baseline miR-21 and miR-205 may be used as prognostic markers for evaluating the tubulointerstitial damage of IgAN. What's more, baseline levels of urinary miRNAs may be predictors to reflect theraputic efficacy and disease progression. 
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Results: The prevalence of AKI in our center was 9.59% (145/1512). The clinicopathologic features were much more severe in AKI group (P < 0.05). Acute tubulointerstitial nephritis (9.7%) was the most predominant intrinsic renal injuries in Chinese IgAN population with AKI instead of macroscopic hematuria related acute tubular injury/necrosis. In multivariate logistic regression analysis, we found that older age, male gender, malignant hypertension, pre-existing impaired kidney function, proteinuria, cellular crescent, fibrocellular crescent, glomerular sclerosis ! 50% were possible risk factors for AKI. The cumulative survival rates without renal progression at 1-year, 3-year, and 
